Boston Scientific acquires Penumbra for $14.5B — largest neurovascular MedTech acquisition ever
Summary
Boston Scientific announced the acquisition of Penumbra Inc for $14.5 billion in January 2026, with shareholders offered $374 per share in a 73% cash and 27% stock mix. Penumbra, a leader in mechanical thrombectomy and neurovascular solutions for stroke, generated approximately $1.4B in 2025 revenue growing 17%+ year-over-year. The deal positions Boston Scientific in large-bore mechanical thrombectomy for stroke alongside its existing neuromodulation portfolio.
Why it matters
At $14.5B, this is the largest neurovascular MedTech acquisition ever and signals that Big MedTech views stroke intervention as the next major growth market. Boston Scientific entering mechanical thrombectomy alongside its existing DBS, SCS, and TMS portfolios creates the broadest neurotech product footprint of any single MedTech company globally.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial